Literature DB >> 6633248

The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival.

A Varki, R Lottenberg, R Griffith, E Reinhard.   

Abstract

We describe here a series of 88 consecutive patients with bone marrow fibrosis. Primary causes for the fibrosis were discovered in 26% of the cases shortly after the initial diagnosis. Pathology review of the remaining cases revealed an 8% incidence of "hairy cell leukemia" that had escaped detection originally. The remaining cases, characterized as having "unexplained bone marrow fibrosis" or "idiopathic myelofibrosis," are the subject of this study. The clinical and laboratory findings are compared to those reported in previous series of selected cases with similar features in which patients were diagnosed as having "agnogenic myeloid metaplasia," "myelosclerosis," or "myelofibrosis." A brief summary of the treatment modalities used, and the clinical course and outcome of these patients are also presented. There was a marked variability in the clinical severity of the disease and in the survival of these patients. A detailed statistical analysis of 40 variables at the time of initial diagnosis showed that the factors that best predicted a poor survival were unexplained fever, weight loss, night sweats, anemia and thrombocytopenia. On the other hand, the size of the spleen or of the liver, the degree of immaturity of the peripheral blood white cells, and the degree of fibrosis or cellularity in the bone marrow biopsy were of no detectable prognostic significance. These findings suggest that in patients with unexplained fibrosis of the bone marrow (the syndrome of idiopathic myelofibrosis) a poor prognosis is not a direct consequence of the marrow fibrosis or the associated extramedullary hematopoiesis, but rather is related to the presence and/or the severity of some unexplained primary marrow defect, which is also often associated with the nonspecific symptoms of a systemic illness.

Entities:  

Mesh:

Year:  1983        PMID: 6633248

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  12 in total

Review 1.  Anemia of Central Origin.

Authors:  Kazusa Ishii; Neal S Young
Journal:  Semin Hematol       Date:  2015-07-09       Impact factor: 3.851

2.  Development of acute leukaemia after idiopathic myelofibrosis.

Authors:  J M Hernández; J F San Miguel; M González; A Orfao; M C Cañizo; C Bascones; J Hernández; A López Borrasca
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

3.  Extramedullary haemopoiesis in the central nervous system: an unusual cause of epilepsy.

Authors:  C Anderson; C Duggan; W F Kealy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-05       Impact factor: 10.154

Review 4.  Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia.

Authors:  M C Le Bousse-Kerdilès; M C Martyré
Journal:  Springer Semin Immunopathol       Date:  1999

5.  Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients.

Authors:  M C Souza; C A Rodrigues; M R R Silva; J Ribeiro; R Tognon; F A Castro; B P Simões; E X Souto; M L Chauffaille
Journal:  Med Oncol       Date:  2013-04-09       Impact factor: 3.064

Review 6.  Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

Authors:  Jan Jacques Michiels; Juergen Thiele
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

7.  Myelofibrosis: Review of clinical and pathological features in fourteen dogs.

Authors:  B Hoff; J H Lumsden; V E Valli; S A Kruth
Journal:  Can Vet J       Date:  1991-06       Impact factor: 1.008

8.  Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival.

Authors:  S Rupoli; L Da Lio; S Sisti; G Campanati; A Salvi; M F Brianzoni; S D'Amico; A Cinciripini; P Leoni
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

9.  Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.

Authors:  Tariq I Mughal; Kris Vaddi; Nicholas J Sarlis; Srdan Verstovsek
Journal:  Int J Gen Med       Date:  2014-01-29

10.  Hepatic manifestations in hematological disorders.

Authors:  Jun Murakami; Yukihiro Shimizu
Journal:  Int J Hepatol       Date:  2013-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.